PhaseFolio

Source-Linked Biotech Diligence

Build the Scientific Case Before You Model the Value

PhaseFolio helps biotech investors and development teams compare relevant programs, verify the evidence behind the differences, and carry a source-linked case into diligence and valuation.

Decision support for serious evaluation. Expert scientific, clinical, financial, legal, and regulatory judgment remains essential.

Startup Program Support

Credits and technical support; no product endorsement implied.

ParticipantGoogle for Startups Cloud ProgramMemberMicrosoft for StartupsParticipantCloudflare for Startups

What This Solves

Less time rebuilding the landscape. Better questions sooner.

The job is not to generate another summary. It is to establish which evidence belongs in the decision, see where it is weak, and preserve the reasoning through every handoff.

  1. 01

    Find the comparison that actually belongs

    Keep indication, mechanism, modality, population, setting, trial design, and current program state in scope so unlike programs are not flattened together.

  2. 02

    See uncertainty before it becomes an assumption

    Supporting, contradictory, incomplete, and missing evidence stays visible with its source, date, scope, and quality state.

  3. 03

    Verify without rebuilding the research

    A material claim travels with the evidence needed to check it, so the next reviewer does not have to begin from an empty page.

  4. 04

    Carry the scientific case into the decision

    Move the sourced comparison into scenarios, valuation, Excel, memos, portfolio review, and signed snapshots instead of recreating it across tools.

The Product Query

For this diligence question, which programs deserve comparison, why were they surfaced, and what evidence supports, contradicts, or limits each comparison?

Current Product and Direction

Start with the science. Keep the decision record intact.

Available Today

Carry the evidence into the decision

Organize asset context, source-linked assumptions, scenarios, valuation, and signed snapshots in one governed record that survives review and handoff.

See the current workflow →

In Development

Make the scientific comparison deeper

Expand indication by indication into coverage-measured program intelligence, trial outcomes, regulatory and deal precedents, and change detection. Partial and missing evidence will remain explicit.

Follow the public research →

Product Preview

See the workflow before the walkthrough.

Follow a deck from structured intake to a reviewable clinical read and a versioned valuation. The example is illustrative and uses synthetic data.

20-Second Product Trailer

From deck to decision

See candidate fields become a reviewable clinical read and a versioned valuation.

PhaseFolio workflow: a pitch deck extracted into a risk-adjusted valuation
PhaseFolio and EB Research Partnership announcement

Featured Announcement · Nonprofit Access Program

PhaseFolio Begins Work With EB Research Partnership

EB Research Partnership will use PhaseFolio to examine valuation assumptions, compare scenarios, organize supporting evidence, and evaluate research programs at both the asset and portfolio level. Access is being provided on a complimentary basis through PhaseFolio’s nonprofit access program.

Read the Full Announcement

This collaboration supports internal evaluation and workflow feedback. It does not imply EB Research Partnership’s endorsement or independent validation of PhaseFolio’s methodologies or outputs.

Public Proof

Inspect the basis, not a slogan.

PhaseFolio publishes the methodology, validation work, versions, and limitations behind its models. These figures are evidence of inspectability, not a promise of investment performance.

12,728+

clinical transitions

The published BIO/QLS 2021 clinical-development transition data behind baseline calibration.

111

drugs backtested

Outcome-labeled public cohorts with methods and study-level caveats available for inspection.

3

validation studies

Published separately so discrimination, calibration, limitations, and failed signals remain visible.

Read the methodology →Review the JHTV case study →Verify a signed snapshot →

Start With a Real Decision

Bring the diligence question. We will show you the workflow.

Walk through the current product on an asset or portfolio problem your team already needs to evaluate.

Request Access